Drug immunosenescence actions on the basis of cell suspension and a method of treatment of acquired immunodeficiency syndrome (hiv) infection, with the use of this medication

 

(57) Abstract:

The invention relates to medicine, in particular to cellular therapy. Patented drug, characterized by a specific composition and quantitative indicators of cell suspension obtained from native or cryopreserved hematopoietic stem cells embryonic liver and/or spleen person. In addition, patented a method of treating acquired immunodeficiency syndrome (HIV) by introducing the above medicinal product chosen from the tissue Bank of different designs to suit the individual indicators of the patient, and with the reintroduction of the drug use of the same sample. The technical result of the invention is the expansion of the means to fight HIV infection. 2 S. and 4 C.p. f-crystals, 41 PL.

The present invention relates to medicine, in particular to cellular therapy, and may find use for the treatment of acquired immunodeficiency syndrome (HIV), and other diseases caused by the occurrence of immunodeficiencies.

In recent years in the field of implementation research cadaveric human EMBRAPA, which allows use of cell suspensions prepared from the tissues of the embryo, to compensate for the lack of functional activity of the damaged, painful tissues. Cell transplantation is an attractive alternative to transplantation of organs and tissues, as the benefits of embryonic cells are that they have not formed a hard individual signs histocompatibility antigen, they engraftment easily and not cause a reaction, graft versus host. In addition, cells have a strong potential for life. They proliferate, differentiate, are the source of huge amounts of biologically active substances.

Currently using cell suspension prepared from embryonic brain, bone marrow, liver, spleen, thymus, pancreas, skin-muscle flap.

They are used to treat blood disorders: primary and secondary myelodepression conditions, immune disorders, nervous disorders, diabetes and others.

The first most successful attempts to use the cell suspensions as drugs are associated with embryonic liver of man.

In recent years, varying by various methods preparation of cell suspensions, as well as various application methods, researchers were able to achieve positive results in the treatment of primary and secondary myelodepression States (Lucarelli G., Izzi So, Porcelini A. Fetal liver transplantation. Alan R. Liss, 1985, p.237-249).

A promising direction in the clinical application of these cell suspensions are disorders of the immune system, in particular in severe combined immunological deficiency. Here are the most significant clinical experience belongs Touraine J. L. (202 transplantation) - Transplantation Proceedings, 1993, v.25, N 1, p.1067-1078.

Currently working Bacchetta R, Roncarolo M. J. J. L. Touraine J. Clin. Invest, 1993, v.91, March, p.l067-1078 shows long-term results of treatment of two patients with severe combined immunodeficiency, when not only recovered the levels of immunity in these patients, but also shows the presence of the split chimerism and the emergence of tolerance to antigens of both host and donor.

The authors also include their experience in the treatment of immune disorders in blood diseases using cell suspensions.

However, use of these the MOU HIV infection is a specific interaction of the envelope protein of HIV (Dr 120) with protein CD4expressed on the surface of immune cells, belonging to the class of T4lymphocytes (helpers/inductors). Significantly reduced the number of cells that carry CD4CD8CD12changes indicator CD4/CD8there polyclonal stimulation of b-lymphocytes and plasma cells, decreases the activity of mononuclear-macrophage system, decreases the number of NK and DN cells.

AIDS patients are observed hematologic disorders that are the result of direct inhibition of hemopoiesis HIV infection, as well as the result of medical treatment, infiltrative processes of inflammatory, infectious or neoplastic in nature. These violations lead to lymphopenia, leukopenia, anemia, thrombocytopenia.

But especially important is the damage of the immune system, the severity of which depends clinical forms of AIDS, the timing of their development, the nature of the flow.

Know the treatment of patients with a comprehensive clinical picture of AIDS by means of transplantation of cell suspensions derived from bone marrow (Hassett J. M. Zaroulis Ch.G. Greenberg, M. L. at all N. Engl. J. Med; 1983, v. 309, N1, p.665).

However, this method Leche the bone marrow requires careful examination of tissue compatibility. In addition, it is necessary to conduct drug preparation of the donor, the recipient, to ensure bacterial decontamination of the intestine. Secondly, despite the identity of the HLA and the ongoing preparation of the acute form of the functioning cells of donor bone marrow are found in more than half of the patients in the form of epidermal necrosis, necrosis of the liver, hepatitis, fungal rejection of the intestinal mucosa and others In the third, restoration of the immune system is selective and short-term (4-6 weeks) and due to lesions of the bone marrow cells of HIV-infection. Clinical improvement is unstable in nature and is rated as doubtful.

The basis of the invention the task is to create such a drug immunosenescence actions on the basis of cell suspension, in which, through the optimal selection of indicators of cellular composition, could strengthen the mechanism immunosenescence and to achieve positive results in treating patients of AIDS (HIV).

The problem is solved in that the medicines immunosenescence actions on the basis of the cell suspension prepared from native or cryopreserved hemopoietic nucleated cells is 5 to 200106/ml, the number of colony forming units granulomonocitarnyi range from 20 to 200103/ml, the number of colony forming units of blasts from 0.5 to 50103/ml and the number of early precursors of haematopoiesis from 1 to 20106/ml.

It was empirically established that the choice of such indicators of cellular composition and their quantitative ratios allow to achieve positive results in the treatment of AIDS.

The authors suggest that this part of the claimed medicinal product allows you to fill in the missing cellular and humoral factors of immunity by proliferation and differentiation of embryonic stem cells in HIV-infected and AIDS patients. In addition, the drug for the claimed composition as a source of biologically active substances, causing a stimulating effect, activating cellular and humoral mechanisms of immunity recipient.

According to the invention it is advisable that when cryoconservation of drug is additionally contained dimethyl sulfoxide in an amount of from 3 to 10%. The choice of the lower limit is determined by the largest possible preservation of cells in cryoconservation, and the top,be the treatment of AIDS, which consists in the introduction of biological material immunosenescence actions, according to the invention as a biological material immunosenescence actions use of patented drug.

The authors believe that medicines on the basis of the aforesaid cell suspensions have never been used for the treatment of patients with AIDS (HIV infection). However, long-term research work on studying the mechanisms of the effects of drugs on the basis of cell suspensions on the processes of treatment of various diseases allows to assert that the cell suspension of the proposed structure very successfully can be used to treat patients with AIDS.

The application of cell suspensions on the basis of hematopoietic and embryonic stem cells hematopoietic organs based on the following mechanisms:

1. Stem cells are transformed under the action of hemopoietic factors in the germ blood, the lack of which has in the body.

2. The Central organs of immunogenesis in patients with AIDS are violated to a lesser extent than the peripheral link presented to T-lymphocytes. Therefore, lymphocytes embryonic proiskhozhdienia significant inhibition of hypersensitivity reactions of the delayed type up to complete anergy, that is why the possible long-term substitution effect without correction immunosuppressants.

4. Along with correction of lymphoid Rostock haematopoiesis is the recovery of myeloid Rostock, including megakaryocytes that finds expression in the increase in the number of erythrocytes, leukocytes, platelets.

5. The issue of sustainability of embryonic stem cell haematopoiesis to HIV infection remains open, although there is clinical evidence of this phenomenon.

6. There are encouraging results in the combined treatment, when the pre-etiotropic therapy reduces the possibility of destruction of embryonic tissue of HIV due to violations of the reproduction of the virus.

7. A method of treating hematopoietic cells embryonic liver and/or spleen person and stem cells of embryonic hematopoiesis hematopoietic organs is particularly indicated for patients with intolerance to AZT and DDL

The possibility of using cell suspensions derived from hematopoietic cells and stem cells of embryonic hematopoiesis hematopoietic organs, confirmed by clinical trials conducted by the authors. logicheskoi remission.

In accordance with one aspect of the present invention, it is expedient patented drug to enter at a dose of 0.5 ml to 8 ml

In addition, it is desirable that this drug was introduced before and/or after therapy etiotropic drugs.

Medication it is advisable to choose from the tissue Bank of different designs to suit the individual indicators of the patient, with re-introduction of the drug use of the same sample.

Hereinafter the invention will become clearer from the following detailed description of its implementation set forth in the specific examples of its implementation.

The best option of carrying out the invention

The drug for the claimed composition can be manufactured using the following method.

Embryos were obtained when induced termination of pregnancy in healthy, pre-screened for the presence of viral and himicheskih infections women using embryos for a period of from 5 to 12 weeks of gestation. In order to preserve the integrity of embryo abortion performed by wakuumaspiratiou. The embryo is transferred into a sterile container with Hanks solution and antibiotics (group aminoglycoside Petri dishes, filled with Hanks solution with antibiotic, where, carefully opening the abdominal cavity, remove the liver, spleen, of which separately prepare cell suspension.

Krovetvorenie bodies placed in a homogenizer, cut into small pieces and ground to a homogeneous mass. Cells are washed from the walls and pestle homogenizer Hanks solution in a measuring tube, passing through the filter for transfusion of blood products, and then through needles of decreasing diameter. Part of the prepared suspension is transferred into a plastic container and sealed. This part is used for the transplantation of native cell suspension. Another part is subjected to cryopreservation.

As cryoprotectant use chemically pure dimethylsulfoxide (DMSO). Before using DMSO passed through millionby filter with a pore diameter of 0.22 μm. With a light mixing cell suspension is added dropwise equal volume of the working solution of DMSO in an amount of from 3 to 10%.

Cell suspension is poured into plastic containers depending on further goals from 0.5 to 2 ml Containers placed in the camera software freezer, working is carried out in the Bank embryonic tissues at 196oC.

After preparation of cell suspension, define the following parameters:

1 - the number of nucleated cells in 1 ml;

2nd-the number of colony forming units granulomonocitarnyi number (CFU GM) in 1 ml;

3 - the number of colony forming units of blasts (CFU BL.) 1 ml;

4th - the number of early precursors of haematopoiesis (CD34in 1 ml.

Next, form a tissue Bank with regard to the studied parameters were within the following limits:

1st from 5 to 200106/ml

2nd-from 20 to 200103/ml

3rd from 0.5 to 50103/ml

4th from 1 to 20106/ml

Prenatal diagnosis involves examination for syphilis, HIV, viral hepatitis B and C, toxoplasmosis, cytomegalovirus infection. Conduct research content containers for bacterial sterility.

Fetal diagnosis includes testing for HIV, viral hepatitis B and C, cytomegalovirus, rubella virus, herpes and toxoplasmosis.

Depending on the clinical treatment of drug administered one of the following methods:

- introduction (transplantation) part of naturehas;

- the introduction of an entire native sample;

- introduction of part or all of cryopreserved material of this sample.

Before and in some cases after transplantation of cell suspension should conduct etiotropic treatment of the patient, for example, azidothymidine in submaximal doses until clinical positive effect, improving the immunological parameters, reduction of the titer of antibodies to HIV and phenomena mielodepressii.

The treatment effect estimate for:

- the duration of clinical remission;

- immunological indicators - total number of lymphocytes, the content of the CD3CD4CD8the coefficient CD4/CD8;

- the number of peripheral blood erythrocytes containing fetal hemoglobin.

Detailed description of the use of patented inventions in the authors ' clinical practice are presented in the following examples.

Example 1

Patient 920034 "T", 37 years old, was admitted to the unit AIDS KNII echs 23.02.93,

Diagnosis: AIDS clinical. Pneumocystis pneumonia in the stage of convalescence. Chronic bronchitis of the smoker. Condition after suffering encephalitis. Candidiasis of the intestinal and respiratory ASS="ptx2">

HIV was found in 1990 to September 1992, was treated in Moscow. For the first time in the AIDS KNII echs was 17.09.92-26.10.92, Moved pneumocisty pneumonia.

23.10.92 was transferred to the intensive care unit with herpetic encephalitis after bone marrow puncture, developed lower paraplegia, and neuritis of the facial nerve, as a result of encephalitis.

Complained of constant headaches, periodically increasing, accompanied by nausea, sometimes vomiting, and dizziness, occasional loss of consciousness. Also was bothered by coughing a small amount of sputum, feeling aches in bones and joints, weakness of the muscles of the lower extremities (walks, holding on to a support), facial asymmetry (right-hand neuritis of the facial nerve). Body temperature was periodically increased to 39oC.

Objectively: pale skin, clean. Peripheral lymph nodes are small, up to 0.5 cm in diameter, movable, elastic consistency, painless. Heart sounds sonorous, rhythmic. The breath in his lungs hard, scattered dry rales over the entire surface.

The abdomen is soft, sensitive to palpation in the epigastrium and right hypochondrium.opatijska cells embryonic human liver, conducted 4.03.93 was added to 2.5 ml

Characterization of cell suspension:

sample 3037 C-12H, the age of the embryo 9 weeks, the number of nucleated cells 98106/ml, CFU GM - 26103/ml , CFU BL.- 1,4103/ml, CD34- 2,4106/ml route of administration is intravenous.

After transplantation showed positive: improved General condition, increased emotional tone, improved appetite. After a few days, decreased cough; the patient noted that it became easier to walk, decreased fever. In the lungs remained hard breathing, but no rales were heard.

29.04.93) underwent re-transplantation (same model, introduced 2.5 ml). Discharged 30.04.93, (for family reasons) in a satisfactory condition.

Re was in the block AIDS 13.05.93 -17.07.93, Continued headaches, dizziness, pain in the bones and joints. However, body temperature did not rise, it was noted good appetite, sleep, no cough, decreased facial asymmetry, for short distances the patient walked without support.

After discharge 7.07.93 he was at the place of residence in Odessa, where he had a tinea of the scalp, soprovojdavshie in block AIDS with complaints of headache, irradium in the right and left eye, nousou the pain and difficulty of movements in the joints, fever-37.3 - 38,2oC, nousou epigastric pain, coughing, thick sputum purulent character. In the lungs were heard hard breathing, dry rales on both sides (19.10.93, Pneumocystis 48% field of view).

5.11.93, the third transplantation of cell suspensions of the same sample (1.5 ml). 9.11.93, was a decrease of cough, body temperature is 37.2oC. Pneumocystis were not found. Discharged 11.11.93, in a satisfactory condition.

In tables 1 - 6 the results of laboratory and immunological studies (see below).

Currently, the condition is satisfactory. Monitoring continues.

Example 2

Patient 930002 "In" received in block AIDS KNII echs 23.02.93, Diagnosis: AIDS clinical. Pneumocystis pneumonia in the stage of convalescence. Candidiasis of the oral cavity. Chronic hepatitis with transition to cirrhosis. Chronic iron deficiency anemia. Chronic gastroduodenitis, moderate exacerbation. Diverticulum of the esophagus. Recurrent internal hemorrhoids, acute stage.

For the first time a positive response to Windgenerated chest, 15.01.93 - bronchoscopists figure reinforced fibrous changed, especially in the lower lobes. Roots tyazhistye, in the large calcite. Conclusion: Chronic bronchitis. During treatment received Biseptol, nystatin, mukaltin, multivitamin. Was discharged in good condition.

When re-entering 23.02.93 he complained of weakness, fatigue, poor appetite.

Objectively: pale skin. Peripheral lymph nodes: palpable zadaszenia, submandibular, elbow, groin, up to 1.0 cm in diameter, movable, painless, elastic consistency.

Heart sounds moderately attenuated sonority and rhythmic. In the lungs, the breathing is weak, with a hard tone. The abdomen is soft, painless. The edge of the liver 4 cm stands from under the costal arch. Spleen not palpated. Peripheral edema no.

4.03.93, patients received transplantation of cell suspensions derived from hematopoietic cells of the embryonic liver and spleen. Characterization of cell suspension: a sample 3037C-37HL, the age of the embryo 7 weeks, put 2.5 ml, the number of nucleated cells - 37106/ml, CFU-GM - 22103/ml, CFU nl. - 1,8103/ml, CD34- 3,4106/m is etica, weakness decreased. There was a decrease in hemoglobin and the positive reaction of yens Gregersen collection, however, when viewed by the surgeon bleeding is not detected. The appointment of a hematologist took tardyferon, the patient's condition was stable.

In tables 7-12 the results of laboratory and immunological studies (see below).

Discharged in a satisfactory condition. Monitoring continues.

Example 3

Patient 910004 "H", 48, enrolled in block AIDS KNII echs 24.05.93,

Diagnosis: AIDS clinical. Pneumocystis pneumonia in the stage of convalescence. Nikomachos. The WPW syndrome.

First HIV-positive diagnosed in 1991

In October 1992 he moved Pneumocystis pneumonia.

Enrolled in a planned manner for examination.

Complained of periodic fever up to subfebrile figures, pain in the lower back. On radiographs of the chest 2.06.93 G. : lung fields without visible pathology. Determined by the expansion of the shadow of the mediastinum on the right path in the area of discharge of the upper lobe bronchus and the root of the lung is most likely due to the increase lymphatici cells embryonic human liver. Characterization of cell suspension: a sample S-24N, the age of the embryo 6 weeks, put 1.5 ml, the number of cells 14106/ml, CFU GM - 27103/ml, CFU nl. - 3,4103/ml, CD34- 3,4106/ml.

After transplantation, there was an improvement in General condition, decrease in temperature, pain in the back.

1.07.93 he started fasting, during which there was weakness, sweating. With 15.07.93, high fever, a rare cough in the morning with a small amount of sputum.

23.07.93 was diagnosed with right-sided inferior pneumonia. Appointed anticipated in remission.

With 6.08.93, received gentamicin, Biseptol, Cefazolin, methenamine acid.

Radiography of the chest 20.08.93, - pneumonic infiltration in the right lung was resolved.

Discharged 25.08.93, in a satisfactory condition.

In tables 13-17 the results of laboratory and immunological studies (see below).

The patient periodically examined in block AIDS. No complaints, maintained in a satisfactory condition.

Monitoring continues.

Example 4

Patient 900007 " the smoker.

HIV was found in 1990, when he was in the hospital with cholecystitis.

17.05.-7.06.90, was treated in the block AIDS about lacunar angina, this time is in the dispensary, periodically examined.

3.06.93, the patient is a transplantation of cell suspensions prepared from native hematopoietic cells embryonic human liver. Characterization of cell suspension: a sample 3037 - N, the age of the embryo 8 weeks, put 3 ml, the number of nucleated cells 78106/ml, CFU GM - 44103/ml, CFU nl. - 2,4103/ml, CD34- 2,7106/ml route of administration is intravenous.

Transplantation patient satisfactorily, changes in health are not marked.

23.07.93, was treated in the unit AIDS in connection with acute left-sided inferior pneumonia (x-ray of the chest 23.07.94, in the lower lobe of the left lung infiltrative changes in the form of focal shadows. The root of the jet. The right lung without features). When sputum Pneumocystis not identified. In General condition there was a strong weakness, sweating, coughing, a small amount of sputum. B is enom condition.

1.09.93) underwent re-transplantation of cryopreserved cell suspension (same sample), which the patient satisfactorily, 16.09.93, noted the rise in body temperature of 37.7oC, accompanied by weakness, feeling aches all over the body, headache, 17.09.93, in a normal condition.

In tables 18-23 the results of laboratory and immunological studies (see below).

Discharged 24.09.93, in a satisfactory condition.

Up to the present time the condition of the patient is satisfactory.

Example 5

Patient 930024 "D", 36, enrolled in block AIDS KNII echs 27.08.93,

Diagnosis: AIDS clinical. Generalized lymphadenopathy. Candidiasis of the oral cavity. Giardiasis intestinal. Enteritis proteaceae etiology. Hypochromic anemia.

Identified as HIV-infected in 1993, in connection with long-term (3 months) fever to 38-38,5oC is not curable with antibiotics (treated himself), as well as long-lasting diarrhea, and was tested for HIV.

Upon receipt complained of severe weakness, sweating, fever up to 39oC, headaches, poor sleep, STU is pale. Peripheral lymph nodes are mobile, painless, elastic consistency, zadaszenia multiple of 0.5 cm, axillary groups of 3-5 to 1 cm, inguinal - 0.5 cm heart sounds weak sonority, rhythm, tachycardia. The breath in the lungs vesicular, wheezing is not heard. The abdomen is soft, painless. The edge of the liver 2 cm stands from under the costal arch. Peripheral edema no.

28.08.93, radiograph of the chest: in the upper lobe of the left lung infiltrative changes amid increased bronchoscopists picture. The left root is extended, unstructured. Conclusion: pneumonia, localized in the upper lobe of the left lung.

When viewed ENT: chronic subtropically pharyngitis.

Treatment: Cefazolin, Biseptol, Retrovir, metronidazole.

Despite ongoing therapy, the fever is not reduced, continued diarrhea, increased weakness, progressed anemia, increased lymph nodes.

Diagnosed AIDS clinical. Septic condition.

12.09.93, patients received transplantation of cell suspensions of fetal human liver. Characterization of cell suspension: a sample 3037-46N, age SUP>3/ml, CD341,5106/ml route of administration is intraperitoneal.

After transplantation the patient's condition has improved somewhat. Decreased temperature to subfebrile, decreased effects of intoxication, weakness, sweating.

In tables 24-29 the results of laboratory and immunological studies (see below).

At the insistence of the patient was discharged home. The resolution of pneumonia during the month. Currently, the condition is satisfactory, continue taking Retrovir.

Example 6

Patient 91005 "H", 25, enlisted in the block AIDS KNII echs 21.04.93,

Diagnosis: AIDS clinical. Pneumocystis pneumonia in the stage of reconvalescence. Candidiasis of the oral mucosa, bronchial tubes. Allergic blepharoconjunctivitis. Chronic hepatitis with transition to cirrhosis. Portal hypertension. Ascites. Hepatolienal syndrome.

HIV infection diagnosed in 1989, was observed in Moscow, received azidothymidine.

With 15.12.91 was observed in block AIDS.

With 11.11. on 22.12.92, was treated in the AIDS diagnosis AIDS. Pneumocystis pneumonia. With 24.11 on 22.12.92, were treated with azidothymidine in a dose of 1000 mg/day, when the extract was recome in block AIDS. Took Retrovir with 18.02.93 g at a dose of 1000 mg per day, with a 6.03. on 16.03.93 g 750 mg per day, was discharged with the recommendation to continue taking Retrovir 500 mg per day for several weeks. During treatment with Retrovir improved health (decreased cough, increased body weight 4-5 kg), and increased evidence of cellular immunity.

Upon receipt 21.04.93 he complained of weakness, dry cough, nousou pain in the right hypochondrium, recurrent nosebleeds, burning sensation of the tongue, fatigue, pain in the throat when swallowing, burning sensation in the eyes.

Objectively: General condition is satisfactory. The skin is normal. Palpable peripheral lymph nodes: submandibular, zadaszenia chain in diameter up to 0.5 cm, axillary groups of 3 to 5 in diameter of 0.7-1.0 cm, lymph nodes elastic consistency, mobile, painless.

Heart sounds moderately attenuated sonority, rhythm, systolic murmur at the apex. In the lungs vesicular breathing. The abdomen is soft, sensitive in the right hypochondrium, slightly increased in volume due to ascites. The edge of the liver 5 cm stands from under the costal arch. Is palpated most dense spleen.

3.05.93 Euu patient satisfactorily. Characterization of cell suspension: a sample 3037-N, the age of the embryo 7 weeks, put 2 ml, the number of nucleated cells 28106/ml, CFU GM - 23103/ml, CFU nl. - 2,4103/ml, CD34- 1,8106/ml route of administration is intravenous.

After transplantation showed improvement of appetite, the patient felt more cheerful.

26.05.93 was discharged in a satisfactory condition. From further receiving Retrovir flatly refused.

In tables 30-35 the results of laboratory and immunological studies (see below).

Monitoring continues.

Example 7

Patient 930009 "At", 41, entered in block AIDS KNII echs 24.03.93,

Diagnosis: AIDS clinical. Disseminated tuberculosis. Candidiasis of the oral cavity, intestines.

HIV was found in March 1993. Since the end of December 1992 notes General malaise, headache, fever-37.3-38oC, pain in the joints of the lower limbs and the muscles of the legs, feeling aches in all my bones and joints, chilling.

2.02.93, for the first time has addressed to the doctor diagnosed arthritis.

Consulted a hematologist 11.02.93 was: wow hepatitis, manifestations of hypersplenism (HB-96 g/l, a blood clot.-124000).

Took ascorbic acid, folic acid, vitamin B1B6B12, nicotinic acid, splenin, aspirin, indomethacin.

2.03.93, blood test: HB - 105 g/l, er - 3,81012/l, C. p. - 0.9, platelets - 135109/l, ESR - 5 mm/hour.

With 4.03.93, took prednisone. After the start of the course noted improvement in health (decreased pain, a feeling of stiffness in the joints). With 28.03.93, got Retrovir. With 6.04.93, Biseptol intravenously.

Radiography of the chest 7.04.93 G.: on the background of pneumosclerosis throughout the lungs multiple focal infiltrative shadow character. The roots extended. Conclusion: small pneumonia should be differentiated with focal tuberculosis.

After consulting a specialist assigned to anti-TB therapy rifampicin, ethambutol, isoniazid, streptomycin. With 21.04.93, body temperature decreased, and further kept 36.4-36,8oC.

With a decrease in temperature improved the General condition disappeared shortness of breath, less coughing, weakness. However, continued to disturb pains in the joints, especially of the hands, periodically tackleton suspension of hematopoietic cells of the embryonic human liver. Characterization of cell suspension: a sample 3037 - N, the age of the embryo 10 weeks, put 4 ml, the number of nucleated cells 142106/ml, CFU GM - 64103/ml, CFU nl. - 1,3103/ml, CD341,8106/ml route of administration is intraosseous.

Transplantation patient satisfactorily, although the next day in the morning, increased body temperature up to 37.2oC. Night temperature was normalized, 20.07.93, morning body temperature of the patient has increased to 38oC, there was a redness of the skin of the forearms, lower limbs, itching (in the General analysis of blood eosinophils 9%). The next day after taking diazoline in a normal condition.

With 27.07.93, patient notes, for the first time in the hospital in a satisfactory condition. Decreased headaches and dizziness, fatigue, no joint pain and right upper quadrant, improved appetite, the patient can perform physical work.

Satisfactory health was during the week, 6.08.93, appeared a slight redness of the skin of the chest, upper and lower extremities, itching and fever up to 38oC. the Temperature was kept for two days,the result is normalized.

10.09.93 was discharged home in good condition with recommendations to continue anti-TB therapy.

In tables 36-41 the results of laboratory and immunological studies (see below).

Monitoring continues.

Thus, the proposed drug and the treatment of acquired immunodeficiency syndrome (HIV) infection, with the use of this drug can:

to achieve clinical remission of the disease;

to improve immunological parameters;

to restore haematopoiesis;

- to reduce the phenomenon of intoxication.

The claimed medicinal preparation on the basis of cell suspension may be used alone, especially in cases of intolerance and contraindications to the use of etiotropic therapy, and in schemes of combined treatment.

In addition, the cell suspension of the claimed composition can be stored in the pharmacy-banks of cryopreserved tissues and, given the absence of the need to identify antigens of the major histocompatibility suggest, if indicated, a simpler application than, for example, the transfusion of blood.

1. the x or cryopreserved hematopoietic stem cells embryonic liver and/or spleen, characterized in that the number of nucleated cells in this suspension is from 5 to 200106/ml, the number of colony forming units granulomonocitarnyi range from 20 to 200103ml, the number of colony forming units of blasts from 0.5 to 10103/ml, the number of early precursors of haematopoiesis from 1 to 20106/ml.

2. Drug under item 1, characterized in that when the cryoconservation of cell suspension further comprises dimethyl sulfoxide in an amount of from 3 to 10%.

3. A method of treating acquired immunodeficiency syndrome (HIV), which consists in injecting a biological material immunosenescence steps, characterized in that the biological material immunosenescence steps used drug under item 1.

4. The method according to p. 3, characterized in that said drug is administered in a dose of 0.5 ml to 8 ml

5. The method according to p. 4, characterized in that said drug is administered before or after therapy etiotropic drugs.

6. The method according to any of paragraphs.3-5, characterized in that the drug is chosen from the tissue Bank of different samples with regard to indie is

 

Same patents:

The invention relates to medicine, namely to preparations for the diagnosis of syphilis enzyme immunoassay methods

The invention relates to medicine, more specifically to Oncology, and can be used in the diagnosis of malignant tumors

The invention relates to medicine, in particular to addiction

The invention relates to the field of immunology, in particular clinical immunology, and for determining the functional activity and the degree of dysfunction of B-systems of immunity

The invention relates to medicine, namely to allergodiagnostic HFRS

The invention relates to medicine, more specifically to the Neuroimmunology, namely to test for antigens associated with multiple sclerosis
The invention relates to biotechnology and genetic engineering and can be used in microbiological industry and medicine to develop a highly effective preventive and diagnostic tools in the fight against tick-borne encephalitis virus (VIK)

The invention relates to biotechnology

The invention relates to medical radiobiology and can be used for the treatment of radiation injured mammals

The invention relates to medicine, in particular for cell therapy and can be used for the treatment of diseases caused by disorders of the immune system, for example, diabetes

The invention relates to medical radiobiology and can be used in the treatment of irradiated mammalian

The invention relates to medicine, namely to the means for correction of hyperlipidemia
The invention relates to medicine, namely to Hepatology and can be used in the treatment of liver failure in chronic liver disease, and may also find application in the surgical wards for preoperative preparation of patients, infectious diseases, intensive care units and intensive care
The invention relates to medicine, namely to Oncology, and for the treatment of patients with advanced tumors of the abdominal cavity
The immune method // 2131257
The invention relates to the field of therapeutic and preventive medicine and can be used to immunocorrective in the prevention and treatment of seasonal colds accompanied by a reduction in immunity
Up!